This information will be helpful to guide the patient selection strategy for the clinical development of SHP2 inhibitors not only in cancers with genetic alterations of FGFR such as gastric cancer (FGFR2 amplification) [43], hepatocellular carcinoma (FGF19-FGFR4 activation) [44] and cholangiocarcinoma (FGF19-FGFR4 activation) [45] but also in KRAS or BRAF mutant cancers in combination with MAPK inhibitors to prevent the pathway feedback activation. The gene discussed is FGFR4; the disease is cholangiocarcinoma.